2 results
Approved WMORecruiting
Dose Expansion:Primary Objective-*To investigate the antitumor activity of HE3-DXdSecondary Objectives-*To assess the safety and tolerability of HE3-DXd in metastatic or unresectable NSCLC subjects-*To characterize the PK of HE3-DXd, total anti-HER3…
Approved WMORecruiting
Primary objectiveTo demonstrate that talazoparib in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging investigator--assessed Radiographic Progression-free Survival (rPFS), in participants with mCSPC…